Acebutolol
Nimodipine may increase the hypotensive activities of Acebutolol.
Acemetacin
The therapeutic efficacy of Nimodipine can be decreased when used in combination with Acemetacin.
Acepromazine
The risk or severity of hypotension can be increased when Acepromazine is combined with Nimodipine.
Advertisement
Acetyl Sulfisoxazole
The serum concentration of Nimodipine can be increased when it is combined with Acetyl sulfisoxazole.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nimodipine.
Alfuzosin
Alfuzosin may increase the hypotensive activities of Nimodipine.
Advertisement
Aliskiren
Nimodipine may increase the hypotensive activities of Aliskiren.
Alprenolol
Nimodipine may increase the hypotensive activities of Alprenolol.
Ambrisentan
Nimodipine may increase the hypotensive activities of Ambrisentan.
Advertisement
Amifostine
Nimodipine may increase the hypotensive activities of Amifostine.
Amifostine Anhydrous
Nimodipine may increase the hypotensive activities of Amifostine.
Amiloride
The risk or severity of adverse effects can be increased when Nimodipine is combined with Amiloride.
Amiodarone
The serum concentration of Nimodipine can be increased when it is combined with Amiodarone.
Amitriptyline
The risk or severity of hypotension can be increased when Amitriptyline is combined with Nimodipine.
Amlodipine
Amlodipine may increase the hypotensive activities of Nimodipine.
Amobarbital
The metabolism of Nimodipine can be increased when combined with Amobarbital.
Amorolfine
The therapeutic efficacy of Amorolfine can be increased when used in combination with Nimodipine.
Amoxapine
The risk or severity of hypotension can be increased when Amoxapine is combined with Nimodipine.
Amphetamine
Amphetamine may increase the hypotensive activities of Nimodipine.
Amphotericin B
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Nimodipine.
amphotericin B liposomal
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Nimodipine.
Amyl Nitrite
The risk or severity of adverse effects can be increased when Nimodipine is combined with Amyl Nitrite.
Anhydrous Tacrolimus
The serum concentration of Tacrolimus can be increased when it is combined with Nimodipine.
Anidulafungin
The therapeutic efficacy of Anidulafungin can be increased when used in combination with Nimodipine.
Apalutamide
The serum concentration of Nimodipine can be decreased when it is combined with Apalutamide.
Apomorphine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Nimodipine.
Apraclonidine
The risk or severity of adverse effects can be increased when Nimodipine is combined with Apraclonidine.
Aprepitant
The serum concentration of Nimodipine can be increased when it is combined with Aprepitant.
Aripiprazole
Aripiprazole may increase the hypotensive activities of Nimodipine.
Arsenic Trioxide
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nimodipine.
Artemether
The therapeutic efficacy of Artemether can be increased when used in combination with Nimodipine.
Asenapine
The risk or severity of hypotension can be increased when Asenapine is combined with Nimodipine.
Atazanavir
The serum concentration of Nimodipine can be increased when it is combined with Atazanavir.
Atenolol
Atenolol may increase the hypotensive activities of Nimodipine.
Atomoxetine
The serum concentration of Nimodipine can be increased when it is combined with Atomoxetine.
Avanafil
Avanafil may increase the antihypertensive activities of Nimodipine.
Azilsartan
The risk or severity of adverse effects can be increased when Nimodipine is combined with Azilsartan medoxomil.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Nimodipine is combined with Azilsartan medoxomil.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Nimodipine is combined with Azilsartan medoxomil.
Barbexaclone
The metabolism of Nimodipine can be increased when combined with Barbexaclone.
Barbital
The metabolism of Nimodipine can be increased when combined with Barbital.
Benazepril
Nimodipine may increase the hypotensive activities of Benazepril.
Bendroflumethiazide
Nimodipine may increase the hypotensive activities of Bendroflumethiazide.
Benzoic Acid
The therapeutic efficacy of Benzoic Acid can be increased when used in combination with Nimodipine.
Bepridil
Nimodipine may increase the hypotensive activities of Bepridil.
Betaxolol
Betaxolol may increase the hypotensive activities of Nimodipine.
Bethanidine
Bethanidine may increase the hypotensive activities of Nimodipine.
Bifonazole
The therapeutic efficacy of Bifonazole can be increased when used in combination with Nimodipine.
Bimatoprost
Nimodipine may increase the hypotensive activities of Bimatoprost.
Bisoprolol
Nimodipine may increase the hypotensive activities of Bisoprolol.
Boceprevir
The serum concentration of Nimodipine can be increased when it is combined with Boceprevir.
Bortezomib
The serum concentration of Nimodipine can be increased when it is combined with Bortezomib.
Bosentan
The serum concentration of Nimodipine can be decreased when it is combined with Bosentan.
Bosentan Anhydrous
The serum concentration of Nimodipine can be decreased when it is combined with Bosentan.
Bretylium
Nimodipine may increase the hypotensive activities of Bretylium.
Brexpiprazole
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Nimodipine.
Brimonidine
Brimonidine may increase the antihypertensive activities of Nimodipine.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Nimodipine.
Bumetanide
The risk or severity of adverse effects can be increased when Nimodipine is combined with Bumetanide.
Bunazosin
The risk or severity of hypotension can be increased when Bunazosin is combined with Nimodipine.
Bupivacaine
The risk or severity of adverse effects can be increased when Bupivacaine is combined with Nimodipine.
Bupranolol
Nimodipine may increase the hypotensive activities of Bupranolol.
Butenafine
The therapeutic efficacy of Butenafine can be increased when used in combination with Nimodipine.
Butoconazole
The therapeutic efficacy of Butoconazole can be increased when used in combination with Nimodipine.
Cafedrine
Nimodipine may increase the hypotensive activities of Cafedrine.
Calcium Acetate
The therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium Acetate.
Calcium Carbonate
The therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium Carbonate.
CALCIUM CARBONATE, PRECIPITATED
The therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium Carbonate.
Calcium Chloride
The therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium Chloride.
Calcium Chloride Anhydrous
The therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium Chloride.
Calcium Citrate
The therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium Citrate.
Calcium Glubionate
The therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium glubionate.
Calcium gluceptate
The therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium Gluceptate.
Calcium Gluconate
The therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium gluconate.
Calcium Lactate
The therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium lactate.
CALCIUM LEVULINATE
The therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium levulinate.
Canagliflozin
The risk or severity of adverse effects can be increased when Nimodipine is combined with Canagliflozin.
Canagliflozin Anhydrous
The risk or severity of adverse effects can be increased when Nimodipine is combined with Canagliflozin.
Candesartan
Nimodipine may increase the hypotensive activities of Candesartan.
Candesartan Cilexetil
Nimodipine may increase the hypotensive activities of Candesartan cilexetil.
Captopril
Nimodipine may increase the hypotensive activities of Captopril.
Carbamazepine
The serum concentration of Nimodipine can be decreased when it is combined with Carbamazepine.
Carteolol
Nimodipine may increase the hypotensive activities of Carteolol.
Carvedilol
Nimodipine may increase the hypotensive activities of Carvedilol.
Casein Allergenic Extract
The therapeutic efficacy of Nimodipine can be decreased when used in combination with Casein.
Caspofungin
The therapeutic efficacy of Caspofungin can be increased when used in combination with Nimodipine.
Celiprolol
Nimodipine may increase the hypotensive activities of Celiprolol.
Ceritinib
The serum concentration of Nimodipine can be increased when it is combined with Ceritinib.
Chlorothiazide
Nimodipine may increase the hypotensive activities of Chlorothiazide.
Chloroxine
The therapeutic efficacy of Chloroxine can be increased when used in combination with Nimodipine.
Chlorpromazine
The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nimodipine.
Chlorthalidone
Chlorthalidone may increase the hypotensive activities of Nimodipine.
Cicletanine
Nimodipine may increase the hypotensive activities of Cicletanine.
Ciclopirox
The therapeutic efficacy of Ciclopirox can be increased when used in combination with Nimodipine.
Cilazapril
Nimodipine may increase the hypotensive activities of Cilazapril.
Cimetidine
The serum concentration of Nimodipine can be increased when it is combined with Cimetidine.
Clarithromycin
The serum concentration of Nimodipine can be increased when it is combined with Clarithromycin.
Clemastine
The serum concentration of Nimodipine can be increased when it is combined with Clemastine.
Clevidipine
The risk or severity of adverse effects can be increased when Nimodipine is combined with Clevidipine.
Clevidipine butyrate
The risk or severity of adverse effects can be increased when Nimodipine is combined with Clevidipine.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Nimodipine.
Clomipramine
The risk or severity of adverse effects can be increased when Clomipramine is combined with Nimodipine.
Clonidine
Clonidine may increase the hypotensive activities of Nimodipine.
Clopidogrel
The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nimodipine.
Clotrimazole
The serum concentration of Nimodipine can be increased when it is combined with Clotrimazole.
Clozapine
The risk or severity of adverse effects can be increased when Clozapine is combined with Nimodipine.
Cobicistat
The serum concentration of Nimodipine can be increased when it is combined with Cobicistat.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Nimodipine.
Cordycepin
The therapeutic efficacy of Cordycepin can be increased when used in combination with Nimodipine.
Crizotinib
The serum concentration of Nimodipine can be increased when it is combined with Crizotinib.
Cryptenamine
Nimodipine may increase the hypotensive activities of Cryptenamine.
Curcumin
The serum concentration of Nimodipine can be increased when it is combined with Curcumin.
Cyclopenthiazide
Nimodipine may increase the hypotensive activities of Cyclopenthiazide.
Cyclosporine
The serum concentration of Nimodipine can be increased when it is combined with Cyclosporine.
Cyclothiazide
Nimodipine may increase the hypotensive activities of Cyclothiazide.
Dabrafenib
The serum concentration of Nimodipine can be decreased when it is combined with Dabrafenib.
Dapagliflozin
The risk or severity of adverse effects can be increased when Nimodipine is combined with Dapagliflozin.
Dapiprazole
The risk or severity of hypotension can be increased when Dapiprazole is combined with Nimodipine.
Darunavir
The serum concentration of Nimodipine can be increased when it is combined with Darunavir.
Dasatinib
The serum concentration of Nimodipine can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Nimodipine can be increased when it is combined with Dasatinib.
Debrisoquin
Debrisoquin may increase the hypotensive activities of Nimodipine.
Decanoic Acid
The therapeutic efficacy of Capric acid can be increased when used in combination with Nimodipine.
Deferasirox
The serum concentration of Nimodipine can be decreased when it is combined with Deferasirox.
Delavirdine
The serum concentration of Nimodipine can be increased when it is combined with Delavirdine.
Deserpidine
Nimodipine may increase the hypotensive activities of Deserpidine.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Nimodipine.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Nimodipine is combined with Dexmedetomidine.
Dextroamphetamine
The risk or severity of hypotension can be increased when Dextroamphetamine is combined with Nimodipine.
Diazoxide
Diazoxide may increase the hypotensive activities of Nimodipine.
Dichlorphenamide
The risk or severity of adverse effects can be increased when Nimodipine is combined with Diclofenamide.
Dihydralazine
Dihydralazine may increase the hypotensive activities of Nimodipine.
Dihydroergotamine
The serum concentration of Nimodipine can be increased when it is combined with Dihydroergotamine.
Diltiazem
The serum concentration of Nimodipine can be increased when it is combined with Diltiazem.
Dinutuximab
The risk or severity of adverse effects can be increased when Nimodipine is combined with Dinutuximab.
Dipyridamole
The risk or severity of adverse effects can be increased when Nimodipine is combined with Dipyridamole.
Dorzolamide
Nimodipine may increase the hypotensive activities of Dorzolamide.
Doxazosin
Doxazosin may increase the hypotensive activities of Nimodipine.
Doxepin
The risk or severity of hypotension can be increased when Doxepin is combined with Nimodipine.
Doxycycline
The serum concentration of Nimodipine can be increased when it is combined with Doxycycline.
Doxycycline Anhydrous
The serum concentration of Nimodipine can be increased when it is combined with Doxycycline.
Dronedarone
The serum concentration of Nimodipine can be increased when it is combined with Dronedarone.
Droperidol
The risk or severity of hypotension can be increased when Droperidol is combined with Nimodipine.
Duloxetine
Nimodipine may increase the orthostatic hypotensive activities of Duloxetine.
Econazole
The therapeutic efficacy of Econazole can be increased when used in combination with Nimodipine.
Econazole Nitrate
The therapeutic efficacy of Econazole can be increased when used in combination with Nimodipine.
Efavirenz
The serum concentration of Nimodipine can be decreased when it is combined with Efavirenz.
Efinaconazole
The therapeutic efficacy of Efinaconazole can be increased when used in combination with Nimodipine.
Empagliflozin
The risk or severity of adverse effects can be increased when Nimodipine is combined with Empagliflozin.
Enalapril
Nimodipine may increase the hypotensive activities of Enalapril.
Enalaprilat
Nimodipine may increase the hypotensive activities of Enalaprilat.
Enalaprilat Anhydrous
Nimodipine may increase the hypotensive activities of Enalaprilat.
Enzalutamide
The serum concentration of Nimodipine can be decreased when it is combined with Enzalutamide.
Epinephrine
The risk or severity of hypotension can be increased when Epinephrine is combined with Nimodipine.
Eplerenone
The risk or severity of adverse effects can be increased when Nimodipine is combined with Eplerenone.
Epoprostenol
Nimodipine may increase the hypotensive activities of Epoprostenol.
Eprosartan
Nimodipine may increase the hypotensive activities of Eprosartan.
Erythromycin
The serum concentration of Nimodipine can be increased when it is combined with Erythromycin.
Escitalopram
The risk or severity of hypotension can be increased when Escitalopram is combined with Nimodipine.
Esmolol
The risk or severity of adverse effects can be increased when Esmolol is combined with Nimodipine.
Ethacrynate
The risk or severity of adverse effects can be increased when Nimodipine is combined with Etacrynic acid.
Ethacrynic Acid
The risk or severity of adverse effects can be increased when Nimodipine is combined with Etacrynic acid.
Felodipine
Nimodipine may increase the hypotensive activities of Felodipine.
Fenoldopam
Nimodipine may increase the hypotensive activities of Fenoldopam.
Ferulic Acid
Nimodipine may increase the hypotensive activities of Ferulic acid.
Fluconazole
The serum concentration of Nimodipine can be increased when it is combined with Fluconazole.
Flucytosine
The therapeutic efficacy of Flucytosine can be increased when used in combination with Nimodipine.
Fluoxetine
The serum concentration of Nimodipine can be increased when it is combined with Fluoxetine.
Flupenthixol
The risk or severity of hypotension can be increased when Flupentixol is combined with Nimodipine.
Fluvoxamine
The serum concentration of Nimodipine can be increased when it is combined with Fluvoxamine.
Fosamprenavir
The serum concentration of Nimodipine can be increased when it is combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Nimodipine can be increased when it is combined with Fosaprepitant.
Fosinopril
Nimodipine may increase the hypotensive activities of Fosinopril.
Fosphenytoin
The serum concentration of Nimodipine can be decreased when it is combined with Fosphenytoin.
Fostamatinib
Fostamatinib may increase the antihypertensive activities of Nimodipine.
Furazolidone
Furazolidone may increase the hypotensive activities of Nimodipine.
Furosemide
The risk or severity of adverse effects can be increased when Nimodipine is combined with Furosemide.
Fusidate
The serum concentration of Nimodipine can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Nimodipine can be increased when it is combined with Fusidic Acid.
Glyphosate
The therapeutic efficacy of Glyphosate can be increased when used in combination with Nimodipine.
Griseofulvin
The therapeutic efficacy of Griseofulvin can be increased when used in combination with Nimodipine.
Griseofulvin microsize
The therapeutic efficacy of Griseofulvin can be increased when used in combination with Nimodipine.
Guanabenz
Nimodipine may increase the hypotensive activities of Guanabenz.
Guanadrel
Guanadrel may increase the hypotensive activities of Nimodipine.
Guanethidine
Nimodipine may increase the hypotensive activities of Guanethidine.
Guanfacine
Guanfacine may increase the hypotensive activities of Nimodipine.
Haloprogin
The therapeutic efficacy of Haloprogin can be increased when used in combination with Nimodipine.
Halothane
The risk or severity of adverse effects can be increased when Halothane is combined with Nimodipine.
Hexetidine
The therapeutic efficacy of Hexetidine can be increased when used in combination with Nimodipine.
Hexobarbital
The metabolism of Nimodipine can be increased when combined with Hexobarbital.
Hydralazine
Hydralazine may increase the hypotensive activities of Nimodipine.
Hydrochlorothiazide
Nimodipine may increase the hypotensive activities of Hydrochlorothiazide.
Hydroflumethiazide
Nimodipine may increase the hypotensive activities of Hydroflumethiazide.
Hypoxis hemerocallidea root extract
The serum concentration of Nimodipine can be decreased when it is combined with St. John's Wort.
Idelalisib
The serum concentration of Nimodipine can be increased when it is combined with Idelalisib.
Iloperidone
The risk or severity of hypotension can be increased when Iloperidone is combined with Nimodipine.
Iloprost
The risk or severity of adverse effects can be increased when Iloprost is combined with Nimodipine.
Imatinib
The serum concentration of Nimodipine can be increased when it is combined with Imatinib.
Imidapril
Nimodipine may increase the hypotensive activities of Imidapril.
Imipramine
The risk or severity of adverse effects can be increased when Imipramine is combined with Nimodipine.
Indapamide
Nimodipine may increase the hypotensive activities of Indapamide.
Indinavir
The serum concentration of Nimodipine can be increased when it is combined with Indinavir.
INDINAVIR ANHYDROUS
The serum concentration of Nimodipine can be increased when it is combined with Indinavir.
Indoramin
Indoramin may increase the hypotensive activities of Nimodipine.
Iproniazid
Iproniazid may increase the hypotensive activities of Nimodipine.
Irbesartan
Nimodipine may increase the hypotensive activities of Irbesartan.
Isavuconazole
The serum concentration of Nimodipine can be increased when it is combined with Isavuconazole.
Isavuconazonium
The serum concentration of Nimodipine can be increased when it is combined with Isavuconazonium.
Isocarboxazid
Isocarboxazid may increase the hypotensive activities of Nimodipine.
Isoconazole
The therapeutic efficacy of Isoconazole can be increased when used in combination with Nimodipine.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Nimodipine.
Isosorbide Dinitrate
The risk or severity of adverse effects can be increased when Nimodipine is combined with Isosorbide Dinitrate.
Isosorbide Mononitrate
The risk or severity of adverse effects can be increased when Nimodipine is combined with Isosorbide Mononitrate.
Isoxsuprine
The risk or severity of adverse effects can be increased when Nimodipine is combined with Isoxsuprine.
Isradipine
The serum concentration of Nimodipine can be increased when it is combined with Isradipine.
Itraconazole
The serum concentration of Nimodipine can be increased when it is combined with Itraconazole.
Ivacaftor
The serum concentration of Nimodipine can be increased when it is combined with Ivacaftor.
Ketanserin
Ketanserin may increase the hypotensive activities of Nimodipine.
Ketoconazole
The serum concentration of Nimodipine can be increased when it is combined with Ketoconazole.
Labetalol
Nimodipine may increase the hypotensive activities of Labetalol.
Lacidipine
Nimodipine may increase the hypotensive activities of Lacidipine.
Latanoprost
Nimodipine may increase the hypotensive activities of Latanoprost.
Lercanidipine
Nimodipine may increase the hypotensive activities of Lercanidipine.
Levobunolol
The risk or severity of adverse effects can be increased when Nimodipine is combined with Levobunolol.
Levobupivacaine
The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nimodipine.
Levodopa
Nimodipine may increase the orthostatic hypotensive activities of Levodopa.
Levosimendan
The risk or severity of adverse effects can be increased when Levosimendan is combined with Nimodipine.
Lisdexamfetamine
The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Nimodipine.
Lisdexamfetamine Dimesylate
The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Nimodipine.
Lisinopril
Nimodipine may increase the hypotensive activities of Lisinopril.
Lisinopril Anhydrous
Nimodipine may increase the hypotensive activities of Lisinopril.
Lofexidine
Nimodipine may increase the hypotensive activities of Lofexidine.
Lopinavir
The serum concentration of Nimodipine can be increased when it is combined with Lopinavir.
Losartan
Nimodipine may increase the hypotensive activities of Losartan.
Lovastatin
The serum concentration of Nimodipine can be increased when it is combined with Lovastatin.
Luliconazole
The serum concentration of Nimodipine can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Nimodipine can be decreased when it is combined with Lumacaftor.
Macitentan
Nimodipine may increase the hypotensive activities of Macitentan.
Magnesium Hydroxide
The risk or severity of hypotension and neuromuscular blockade can be increased when Nimodipine is combined with Magnesium hydroxide.
Magnesium Oxide
The risk or severity of hypotension and neuromuscular blockade can be increased when Nimodipine is combined with Magnesium oxide.
Magnesium Salicylate
The risk or severity of hypotension and neuromuscular blockade can be increased when Nimodipine is combined with Magnesium salicylate.
Magnesium Sulfate
The risk or severity of hypotension and neuromuscular blockade can be increased when Nimodipine is combined with Magnesium sulfate.
MAGNESIUM SULFATE ANHYDROUS
The risk or severity of hypotension and neuromuscular blockade can be increased when Nimodipine is combined with Magnesium sulfate.
Manidipine
Nimodipine may increase the hypotensive activities of Manidipine.
Mannitol
The risk or severity of adverse effects can be increased when Nimodipine is combined with Mannitol.
Mecamylamine
Mecamylamine may increase the hypotensive activities of Nimodipine.
Melatonin
Melatonin may decrease the antihypertensive activities of Nimodipine.
Mephobarbital
The metabolism of Nimodipine can be increased when combined with Methylphenobarbital.
Mepirodipine
Nimodipine may increase the antihypertensive activities of Barnidipine.
Methazolamide
The risk or severity of adverse effects can be increased when Nimodipine is combined with Methazolamide.
Methohexital
The metabolism of Nimodipine can be increased when combined with Methohexital.
Methotrimeprazine
The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Nimodipine.
Methyclothiazide
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nimodipine.
Methyldopa
Nimodipine may increase the hypotensive activities of Methyldopa.
METHYLDOPA ANHYDROUS
Nimodipine may increase the hypotensive activities of Methyldopa.
Methylene blue
Methylene blue may increase the hypotensive activities of Nimodipine.
Methylphenidate
Methylphenidate may decrease the antihypertensive activities of Nimodipine.
Metipranolol
Nimodipine may increase the hypotensive activities of Metipranolol.
Metolazone
Nimodipine may increase the hypotensive activities of Metolazone.
Metoprolol
Metoprolol may increase the hypotensive activities of Nimodipine.
Metyrosine
Nimodipine may increase the hypotensive activities of Metyrosine.
Mibefradil
Nimodipine may increase the hypotensive activities of Mibefradil.
Micafungin
The therapeutic efficacy of Micafungin can be increased when used in combination with Nimodipine.
Miconazole
The therapeutic efficacy of Miconazole can be increased when used in combination with Nimodipine.
Mifepristone
The serum concentration of Nimodipine can be increased when it is combined with Mifepristone.
Miltefosine
The therapeutic efficacy of Miltefosine can be increased when used in combination with Nimodipine.
Minaprine
Minaprine may increase the hypotensive activities of Nimodipine.
Minoxidil
Minoxidil may increase the hypotensive activities of Nimodipine.
Mitotane
The serum concentration of Nimodipine can be decreased when it is combined with Mitotane.
Moclobemide
Moclobemide may increase the hypotensive activities of Nimodipine.
Moexipril
Nimodipine may increase the hypotensive activities of Moexipril.
Molsidomine
Molsidomine may increase the hypotensive activities of Nimodipine.
Morphine
The risk or severity of adverse effects can be increased when Morphine is combined with Nimodipine.
Moxonidine
Moxonidine may increase the hypotensive activities of Nimodipine.
Nabilone
The risk or severity of adverse effects can be increased when Nabilone is combined with Nimodipine.
Nadolol
Nimodipine may increase the hypotensive activities of Nadolol.
Nafcillin
The therapeutic efficacy of Nimodipine can be decreased when used in combination with Nafcillin.
Naftifine
The therapeutic efficacy of Naftifine can be increased when used in combination with Nimodipine.
Natamycin
The therapeutic efficacy of Natamycin can be increased when used in combination with Nimodipine.
Nebivolol
Nimodipine may increase the hypotensive activities of Nebivolol.
Nefazodone
The serum concentration of Nimodipine can be increased when it is combined with Nefazodone.
Nelfinavir
The serum concentration of Nimodipine can be increased when it is combined with Nelfinavir.
Nesiritide
The risk or severity of adverse effects can be increased when Nimodipine is combined with Nesiritide.
Netupitant
The serum concentration of Nimodipine can be increased when it is combined with Netupitant.
Nevirapine
The serum concentration of Nimodipine can be decreased when it is combined with Nevirapine.
Nialamide
Nialamide may increase the hypotensive activities of Nimodipine.
Nicardipine
Nimodipine may increase the hypotensive activities of Nicardipine.
Nicergoline
The risk or severity of hypotension can be increased when Nicergoline is combined with Nimodipine.
Nicorandil
Nicorandil may increase the hypotensive activities of Nimodipine.
Nifedipine
The risk or severity of adverse effects can be increased when Nimodipine is combined with Nifedipine.
Nilotinib
The serum concentration of Nimodipine can be increased when it is combined with Nilotinib.
Nilvadipine
Nimodipine may increase the hypotensive activities of Nilvadipine.
Nisoldipine
Nimodipine may increase the hypotensive activities of Nisoldipine.
Nitrendipine
Nimodipine may increase the hypotensive activities of Nitrendipine.
Nitric Oxide
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Nimodipine.
Nitroglycerin
The risk or severity of adverse effects can be increased when Nimodipine is combined with Nitroglycerin.
Nitroprusside
Nimodipine may increase the hypotensive activities of Nitroprusside.
Nitroxoline
The therapeutic efficacy of Nitroxoline can be increased when used in combination with Nimodipine.
Nortriptyline
The risk or severity of hypotension can be increased when Nortriptyline is combined with Nimodipine.
Nystatin
The therapeutic efficacy of Nystatin can be increased when used in combination with Nimodipine.
Obinutuzumab
Nimodipine may increase the hypotensive activities of Obinutuzumab.
Olanzapine
The risk or severity of hypotension can be increased when Olanzapine is combined with Nimodipine.
Olaparib
The serum concentration of Nimodipine can be increased when it is combined with Olaparib.
Olmesartan
Olmesartan may increase the hypotensive activities of Nimodipine.
Osimertinib
The serum concentration of Nimodipine can be increased when it is combined with Osimertinib.
Oxiconazole
The therapeutic efficacy of Oxiconazole can be increased when used in combination with Nimodipine.
Oxprenolol
Nimodipine may increase the hypotensive activities of Oxprenolol.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Nimodipine.
Pafuramidine
The therapeutic efficacy of Pafuramidine can be increased when used in combination with Nimodipine.
Palbociclib
The serum concentration of Nimodipine can be increased when it is combined with Palbociclib.
Paliperidone
The risk or severity of hypotension can be increased when Paliperidone is combined with Nimodipine.
Papaverine
The risk or severity of adverse effects can be increased when Nimodipine is combined with Papaverine.
Paregoric
The risk or severity of adverse effects can be increased when Morphine is combined with Nimodipine.
Pargyline
Pargyline may increase the hypotensive activities of Nimodipine.
Penbutolol
Nimodipine may increase the hypotensive activities of Penbutolol.
Pentamidine
The therapeutic efficacy of Pentamidine can be increased when used in combination with Nimodipine.
Pentobarbital
The serum concentration of Nimodipine can be decreased when it is combined with Pentobarbital.
Pentoxifylline
Pentoxifylline may increase the hypotensive activities of Nimodipine.
Periciazine
The risk or severity of hypotension can be increased when Propericiazine is combined with Nimodipine.
Perindopril
Nimodipine may increase the hypotensive activities of Perindopril.
Phenelzine
Phenelzine may increase the hypotensive activities of Nimodipine.
Phenobarbital
The serum concentration of Nimodipine can be decreased when it is combined with Phenobarbital.
Phenoxybenzamine
Nimodipine may increase the hypotensive activities of Phenoxybenzamine.
Phentolamine
Nimodipine may increase the hypotensive activities of Phentolamine.
Phentolamine Mesylate
Nimodipine may increase the hypotensive activities of Phentolamine.
Phenytoin
The serum concentration of Nimodipine can be decreased when it is combined with Phenytoin.
Pinacidil
Pinacidil may increase the hypotensive activities of Nimodipine.
Pindolol
Nimodipine may increase the hypotensive activities of Pindolol.
Pipamperone
The risk or severity of adverse effects can be increased when Pipamperone is combined with Nimodipine.
Pizotyline
The risk or severity of hypotension can be increased when Pizotifen is combined with Nimodipine.
Polythiazide
Nimodipine may increase the hypotensive activities of Polythiazide.
Posaconazole
The serum concentration of Nimodipine can be increased when it is combined with Posaconazole.
Pramipexole
The risk or severity of adverse effects can be increased when Pramipexole is combined with Nimodipine.
Prazosin
Prazosin may increase the hypotensive activities of Nimodipine.
Primidone
The serum concentration of Nimodipine can be decreased when it is combined with Primidone.
Procaine
Procaine may increase the hypotensive activities of Nimodipine.
Procarbazine
Procarbazine may increase the hypotensive activities of Nimodipine.
Promazine
The risk or severity of hypotension can be increased when Promazine is combined with Nimodipine.
Propiomazine
The risk or severity of hypotension can be increased when Propiomazine is combined with Nimodipine.
Propiverine
The risk or severity of hypotension can be increased when Propiverine is combined with Nimodipine.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Nimodipine.
Propranolol
Nimodipine may increase the hypotensive activities of Propranolol.
Quetiapine
The risk or severity of adverse effects can be increased when Nimodipine is combined with Quetiapine.
Quetiapine fumarate
The risk or severity of adverse effects can be increased when Nimodipine is combined with Quetiapine.
Quinapril
Nimodipine may increase the hypotensive activities of Quinapril.
Quinidine
The serum concentration of Quinidine can be decreased when it is combined with Nimodipine.
Quinine
Quinine may increase the hypotensive activities of Nimodipine.
Racepinephrine
The risk or severity of hypotension can be increased when Racepinephrine is combined with Nimodipine.
Ramipril
Ramipril may increase the hypotensive activities of Nimodipine.
Ranolazine
The serum concentration of Nimodipine can be increased when it is combined with Ranolazine.
Rasagiline
Rasagiline may increase the hypotensive activities of Nimodipine.
Remifentanil
The risk or severity of adverse effects can be increased when Remifentanil is combined with Nimodipine.
Rescinnamine
Nimodipine may increase the hypotensive activities of Rescinnamine.
Reserpine
Reserpine may increase the hypotensive activities of Nimodipine.
Rifabutin
The serum concentration of Nimodipine can be decreased when it is combined with Rifabutin.
Rifampin
The serum concentration of Nimodipine can be decreased when it is combined with Rifampicin.
Rifapentine
The serum concentration of Nimodipine can be decreased when it is combined with Rifapentine.
Rifaximin
The risk or severity of hypotension can be increased when Rifaximin is combined with Nimodipine.
Rilmenidine
Rilmenidine may increase the hypotensive activities of Nimodipine.
Riociguat
Nimodipine may increase the hypotensive activities of Riociguat.
Risperidone
Nimodipine may increase the hypotensive activities of Risperidone.
Rituximab
Nimodipine may increase the hypotensive activities of Rituximab.
Ropinirole
The risk or severity of adverse effects can be increased when Ropinirole is combined with Nimodipine.
Ropivacaine
The risk or severity of adverse effects can be increased when Ropivacaine is combined with Nimodipine.
Rotigotine
The risk or severity of adverse effects can be increased when Rotigotine is combined with Nimodipine.
Rucaparib
The serum concentration of Nimodipine can be increased when it is combined with Rucaparib.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Nimodipine.
Salicylic Acid
The therapeutic efficacy of Salicylic acid can be increased when used in combination with Nimodipine.
Saquinavir
The serum concentration of Nimodipine can be increased when it is combined with Saquinavir.
Saquinavir Mesylate
The serum concentration of Nimodipine can be increased when it is combined with Saquinavir.
Sarilumab
The therapeutic efficacy of Nimodipine can be decreased when used in combination with Sarilumab.
Secobarbital
The metabolism of Nimodipine can be increased when combined with Secobarbital.
Selegiline
Selegiline may increase the hypotensive activities of Nimodipine.
Selexipag
Nimodipine may increase the hypotensive activities of Selexipag.
Sertaconazole
The therapeutic efficacy of Sertaconazole can be increased when used in combination with Nimodipine.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Nimodipine.
Sildenafil
The serum concentration of Nimodipine can be increased when it is combined with Sildenafil.
Silodosin
The risk or severity of hypotension can be increased when Silodosin is combined with Nimodipine.
Siltuximab
The serum concentration of Nimodipine can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Nimodipine can be increased when it is combined with Simeprevir.
Sirolimus
The therapeutic efficacy of Sirolimus can be increased when used in combination with Nimodipine.
Sotalol
The risk or severity of adverse effects can be increased when Nimodipine is combined with Sotalol.
Spirapril
Nimodipine may increase the hypotensive activities of Spirapril.
Spironolactone
The risk or severity of adverse effects can be increased when Nimodipine is combined with Spironolactone.
ST. JOHN'S WORT EXTRACT
The serum concentration of Nimodipine can be decreased when it is combined with St. John's Wort.
Streptokinase
The risk or severity of adverse effects can be increased when Streptokinase is combined with Nimodipine.
Sufentanil
The risk or severity of adverse effects can be increased when Sufentanil is combined with Nimodipine.
Sulconazole
The therapeutic efficacy of Sulconazole can be increased when used in combination with Nimodipine.
Sulfisoxazole
The serum concentration of Nimodipine can be increased when it is combined with Sulfisoxazole.
Tacrolimus
The serum concentration of Tacrolimus can be increased when it is combined with Nimodipine.
Tadalafil
Tadalafil may increase the antihypertensive activities of Nimodipine.
Talinolol
Nimodipine may increase the hypotensive activities of Talinolol.
Tamsulosin
The risk or severity of hypotension can be increased when Tamsulosin is combined with Nimodipine.
Tavaborole
The therapeutic efficacy of Tavaborole can be increased when used in combination with Nimodipine.
Telaprevir
The serum concentration of Nimodipine can be increased when it is combined with Telaprevir.
Telithromycin
The serum concentration of Nimodipine can be increased when it is combined with Telithromycin.
Telmisartan
Nimodipine may increase the hypotensive activities of Telmisartan.
Terazosin
The risk or severity of hypotension can be increased when Terazosin is combined with Nimodipine.
Terbinafine
The therapeutic efficacy of Terbinafine can be increased when used in combination with Nimodipine.
Terconazole
The therapeutic efficacy of Terconazole can be increased when used in combination with Nimodipine.
Terlipressin
Nimodipine may increase the hypotensive activities of Terlipressin.
Thalidomide
The risk or severity of adverse effects can be increased when Thalidomide is combined with Nimodipine.
Theodrenaline
Nimodipine may increase the hypotensive activities of Theodrenaline.
Theophylline
Theophylline may increase the antihypertensive activities of Nimodipine.
Theophylline anhydrous
Theophylline may increase the antihypertensive activities of Nimodipine.
Thiamylal
The metabolism of Nimodipine can be increased when combined with Thiamylal.
Thiopental
The metabolism of Nimodipine can be increased when combined with Thiopental.
Thiopental Sodium
The metabolism of Nimodipine can be increased when combined with Thiopental.
Thioproperazine
The risk or severity of hypotension can be increased when Thioproperazine is combined with Nimodipine.
Thioridazine
The risk or severity of adverse effects can be increased when Thioridazine is combined with Nimodipine.
Thymol
The therapeutic efficacy of Thymol can be increased when used in combination with Nimodipine.
Tibolone
Nimodipine may increase the hypotensive activities of Tibolone.
Ticlopidine
The serum concentration of Nimodipine can be increased when it is combined with Ticlopidine.
Timolol
Timolol may increase the hypotensive activities of Nimodipine.
Timolol Anhydrous
Timolol may increase the hypotensive activities of Nimodipine.
Tioconazole
The therapeutic efficacy of Tioconazole can be increased when used in combination with Nimodipine.
Tizanidine
The risk or severity of adverse effects can be increased when Nimodipine is combined with Tizanidine.
Tocilizumab
The serum concentration of Nimodipine can be decreased when it is combined with Tocilizumab.
Tolazoline
Nimodipine may increase the hypotensive activities of Tolazoline.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Nimodipine.
Tolnaftate
The therapeutic efficacy of Tolnaftate can be increased when used in combination with Nimodipine.
Toloxatone
Toloxatone may increase the hypotensive activities of Nimodipine.
Torsemide
Torasemide may increase the hypotensive activities of Nimodipine.
Trandolapril
Nimodipine may increase the hypotensive activities of Trandolapril.
Tranylcypromine
Tranylcypromine may increase the hypotensive activities of Nimodipine.
Travoprost
Travoprost may increase the hypotensive activities of Nimodipine.
Trazodone
The risk or severity of hypotension can be increased when Trazodone is combined with Nimodipine.
Treprostinil
Treprostinil may increase the hypotensive activities of Nimodipine.
Tretinoin
The risk or severity of adverse effects can be increased when Tretinoin is combined with Nimodipine.
Triamterene
The risk or severity of adverse effects can be increased when Triamterene is combined with Nimodipine.
Tricalcium Phosphate
The therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium Phosphate.
Trichlormethiazide
Nimodipine may increase the hypotensive activities of Trichlormethiazide.
Trifluoperazine
The risk or severity of hypotension can be increased when Trifluoperazine is combined with Nimodipine.
Trimethaphan
Trimethaphan may increase the hypotensive activities of Nimodipine.
Trimetrexate
The therapeutic efficacy of Trimetrexate can be increased when used in combination with Nimodipine.
Trimipramine
The risk or severity of hypotension can be increased when Trimipramine is combined with Nimodipine.
UNOPROSTONE
Nimodipine may increase the hypotensive activities of Unoprostone.
Urapidil
Urapidil may increase the hypotensive activities of Nimodipine.
Valsartan
Valsartan may increase the hypotensive activities of Nimodipine.
Vardenafil
Vardenafil may increase the antihypertensive activities of Nimodipine.
Vemurafenib
The serum concentration of Nimodipine can be decreased when it is combined with Vemurafenib.
Venlafaxine
The serum concentration of Nimodipine can be increased when it is combined with Venlafaxine.
Verapamil
The serum concentration of Nimodipine can be increased when it is combined with Verapamil.
Vincamine
Nimodipine may increase the hypotensive activities of Vincamine.
Vinpocetine
Nimodipine may increase the hypotensive activities of Vinpocetine.
Voriconazole
The serum concentration of Nimodipine can be increased when it is combined with Voriconazole.
Xylometazoline
Nimodipine may increase the hypotensive activities of Xylometazoline.
Yohimbine
Yohimbine may decrease the antihypertensive activities of Nimodipine.
Ziprasidone
The serum concentration of Nimodipine can be increased when it is combined with Ziprasidone.
Zofenopril
Nimodipine may increase the hypotensive activities of Zofenopril.
Zuclopenthixol
The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Nimodipine.
